New immunotherapies are explored to improve the treatment of solid tumours
From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies, although more data are needed
Trials in precision oncology: current snapshot and future innovations
Increased use of molecular profiling is progressively improving decision-making processes in oncology compared with 20 years ago and helping to shape tomorrow’s clinical trials in targeted therapies
Liquid biopsy: novel approaches for early detection of cancer
Multi-omics approaches incorporating cell-free DNA and circulating tumour DNA show potential in early cancer detection and could help personalise treatment by tumour characteristics
Novel liquid biomarkers show promise in predicting clinical outcomes with immunotherapy
Although encouraging results are presented, standardisation of methodology and large-scale clinical trials are needed before potential candidates can be used in routine clinical practice
Precision oncology is the goal today, not a simple slogan
Prof. Lisa Licitra: “Truly pursuing precision medicine means pushing the boundaries of patient selection using molecular biology and artificial intelligence on all big data, not just molecular information”
Breast cancer treatment should be tailored to the tumour biology – not to its hormone-receptor status alone
New insights into breast cancer immunology and genomics support further segmentation of patient subgroups and treatment approaches, says Prof. Sherene Loi